Specifically, the company is putting theranostics at the forefront of its program for the Vienna meeting. It aims to show delegates the benefits of a tailored approach to molecular imaging, including PET and SPECT/CT. This approach includes risk definition, patient stratification, personalized health promotion, and disease prevention strategies.

"Molecular imaging is essential in theranostics, allowing for both non-invasive, repetitive assessment of the compound uptake and characterization of the tumor tissue, and therapy response over time," GE HealthCare noted.

For more information on the company's activities at EANM 2023, go to the company's dedicated webpage and visit GE HealthCare in Hall 4, level 0, booth #416.